10x Genomics Inc. Class A (TXG)
NASDAQ: TXGIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TXG stock chart
Technical analysisKey statistics
All statistics- Market cap
- $6.81B
- Forward P/E
- 597.67
- EPS (TTM)
- -$0.52
- Dividend yield
- None
- 52-week range
- 15.18 – 102.81
- Day range
- 51.30 – 56.44
- Volume / Avg
- 3.23M / 3.36M
- Beta
- —
- Shares outstanding
- 121.46M
52-week range
TXG stock today
10x Genomics (TXG) closed at $51.80 on Nov 20, down 9.72% (-$5.58), versus the S&P 500's 3.70% decline. Shares are 49.6% below their 52-week high of $102.81, set on Oct 6, 2026 and 241.2% above the 52-week low of $15.18, in the middle of the past year's range. TXG is up 217.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 182.4%.
10x Genomics has posted a net loss over the last twelve months (EPS of -$0.52), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About 10x Genomics
Company profile10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits.
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- CEO
- Dr. Serge Saxonov Ph.D.
- Headquarters
- Pleasanton, CA
- Employees
- 1,178
- IPO year
- 2019
- Website
- 10xgenomics.com
Financial highlights
Full financialsIn fiscal 2025, 10x Genomics generated $642.8 million in revenue, up 5.2% from fiscal 2024. 10x Genomics reported a net loss of $43.5 million, compared with a loss of $182.6 million a year earlier. Gross margin was 69.1% (up from 67.9%) and operating margin -9.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $642.82M | $610.78M | $618.73M | $516.41M | $490.49M |
| Growth | +5.25% | -1.28% | +19.81% | +5.28% | +64.13% |
| Net income | $-43.54M | $-182.63M | $-255.10M | $-166.00M | $-58.22M |
| EPS (diluted) | $-0.35 | $-1.52 | $-2.18 | $-1.46 | $-0.53 |
Analyst forecast
ForecastConsensus (17 analysts)
buy
Avg. price target
$68.14+31.54%
- Strong buy 1
- Buy 5
- Hold 11
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.22 vs $-0.29
- Surprise
- +24.14%
TXG news
All TXG news- IDEF, FMED: Big ETF OutflowsNasdaqIDEF, RTX, LMT, TXG
- 10x Genomics Expands Global Research in Blood-Based Diagnostics for Autoimmune Disease with Two New CollaborationsPR Newswire
- 10x Genomics' Xenium Platform to Support Breast Cancer Biomarker StudyNasdaqTXG, ISRG, WST, GKOS
- 10x Genomics Launches Sentira AI Tool to Simplify Cell AnalysisNasdaqTXG, ISRG, WST, GKOS
- 10x Genomics, Inc. Reports Third Quarter 2026 Financial Results and Raises Full Year Revenue GuidanceNasdaq
- Meet the Unstoppable Vanguard ETF Beating the S&P 500 and the Dow Jones in 2026NasdaqVTWO, MSFT, AAPL, GS
- 10x Genomics (TXG) Q3 2026 Earnings Call TranscriptNasdaq
- 10x Genomics forecasts $625M-$635M 2026 revenue as it targets ~50 Atera shipments by year-endSeeking Alpha
10x Genomics peers
Industrials sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BRKRBruker Corporation | 56.46 | -9.08% | $8.62B | vs TXG |
| BIOBio-Rad Laboratories Inc. Class A | 358.90 | -2.34% | $9.65B | vs TXG |
| AVTRAvantor Inc. | 14.84 | -1.85% | $10.06B | vs TXG |
| ALMRAlamar Biosciences Inc. | 26.48 | -7.67% | $1.84B | vs TXG |
| CTKBCytek Biosciences Inc. | 6.12 | -3.16% | $800.40M | vs TXG |
| PACBPacific Biosciences of California Inc. | 1.63 | -7.39% | $508.95M | vs TXG |
| NAUTNautilus Biotechnology Inc. | 2.12 | -2.30% | $270.03M | vs TXG |
| LABStandard BioTools Inc. | 0.631 | +2.82% | $249.11M | vs TXG |
Indexes, lists and sector
10x Genomics stock FAQ
What is 10x Genomics's stock price today?
TXG last traded at $51.80 as of Nov 20, 4:00 PM EST, down 9.72% on the day. Prices are delayed at least 15 minutes.
Who is 10x Genomics's CEO?
Dr. Serge Saxonov Ph.D. is the chief executive officer of 10x Genomics Inc. Class A, which has about 1,178 employees.
What is the TXG 52-week high?
The 52-week high for TXG is $102.81 and the 52-week low is $15.18. The stock is currently 49.6% below its high.